RESUMO
BACKGROUND: Unintentional renal artery occlusion after endovascular aneurysm repair (EVAR) for abdominal aortic aneurysm remains one of the most unfavorable complications. Renal salvage options include percutaneous transluminal renal artery angioplasty (PTRA) and open hepatosplenorenal bypass. However, the usefulness of kidney autotransplantation (AutoTx) remains unclear. CASE PRESENTATION: A 76-year-old woman with a right solitary kidney attributable to a left renal thromboembolism had previously undergone EVAR with a stent graft for an infrarenal aortic aneurysm, which led to ostial occlusion of the right renal artery. In addition, she had undergone PTRA and stenting. Two days before admission, she developed leg edema and hypertension, leading her to visit the hospital. Her serum creatinine level was 2.4 (baseline, 1.0) mg/dL. Acute kidney injury due to renal artery in-stent restenosis was suspected; re-angioplasty was attempted on day 2 of hospitalization, but was unsuccessful. Her renal function did not improve and anuria persisted; thus, hemodialysis was initiated on the same day. The right kidney size (8.6 cm) was preserved relative to her body size, with only mild cortical atrophy. Doppler ultrasonography and mercaptoacetyltriglycine scintigraphy revealed minimal but significant perfusion of the right kidney. Therefore, we considered that kidney perfusion was sustained and renal function could be reversed. On day 25 of hospitalization, right kidney AutoTx to the right iliac fossa was performed to reestablish adequate renal perfusion and reverse the need for dialysis. Soon after the procedure, the patient started passing urine. Her renal function improved; her serum creatinine level decreased to 1.0 mg/dL on day 33 of hospitalization. Hemodialysis was discontinued after the surgery. Zero-hour kidney biopsy showed only mild tubular injury, with neither tubular necrosis nor glomerular abnormalities. CONCLUSIONS: Kidney AutoTx can be performed for patients with renal artery in-stent occlusion after unsuccessful PTRA who previously underwent EVAR. Our case showed successful recovery of renal function nearly 1 month after renal artery occlusion, indicating that revascularization should be considered even if it is delayed, as the kidney might be perfused through collateral circulation.
Assuntos
Aneurisma Aórtico/cirurgia , Implante de Prótese Vascular/efeitos adversos , Procedimentos Endovasculares/efeitos adversos , Transplante de Rim/métodos , Complicações Pós-Operatórias/cirurgia , Obstrução da Artéria Renal/cirurgia , Idoso , Aneurisma Aórtico/diagnóstico , Feminino , Humanos , Complicações Pós-Operatórias/diagnóstico , Complicações Pós-Operatórias/etiologia , Obstrução da Artéria Renal/diagnóstico , Obstrução da Artéria Renal/etiologia , Transplante Autólogo/métodosRESUMO
High daily pill burden affects quality of life and mortality. High interdialytic weight gain (IDWG) is associated with increased mortality. We examined the association between pill burden and IDWG in hemodialysis patients. This cross-sectional study was conducted in six dialysis centers in Japan in June 2017. The exposure was the number of daily tablets, and outcome was defined as 1 day of relative IDWG divided by post-dialysis weight from the previous session. Among 188 outpatients (mean age, 68.7 [SD, 10.3] years; men, 67.0%; median dialysis vintage, 76.0 [interquartile range, 36.5, 131.5] months), the mean number of daily tablets was 19.7 ± 9.9, and mean relative weight gain was 3.5 ± 1.2%. Multiple linear regression analysis showed a regression coefficient of 0.021 (95% confidence interval: 0.004-0.039), indicating that one additional tablet prescription increased the IDWG by 0.021%. In hemodialysis patients, the daily pill burden was a significant, independent risk for increased relative IDWG.
Assuntos
Diálise Renal , Comprimidos/administração & dosagem , Aumento de Peso , Idoso , Estudos Transversais , Feminino , Humanos , Japão , Masculino , Qualidade de Vida , Fatores de RiscoRESUMO
A 77-year-old man with a history of hypertension, prostate hyperplasia, and urolithiasis was admitted for acute kidney injury caused by hypercalcemia. Neck ultrasonography showed a large cyst adjacent to the right lower thyroid lobe. Although a 99mtechnetium sestamibi scan was negative, an extremely high intracystic intact parathyroid hormone level suggested that the cyst had a parathyroid origin and that a functional parathyroid cyst was present. Immunohistochemical staining for the calcium-sensing receptor (CaSR) after right lower parathyroidectomy revealed CaSR-positive cells lining the cyst, indicating that the functional parathyroid cyst had originated from the hemorrhagic degeneration of a parathyroid adenoma.
Assuntos
Adenoma/fisiopatologia , Cinacalcete/uso terapêutico , Hipercalcemia/complicações , Hiperparatireoidismo/tratamento farmacológico , Glândulas Paratireoides/fisiopatologia , Glândulas Paratireoides/cirurgia , Neoplasias das Paratireoides/fisiopatologia , Adenoma/etiologia , Adenoma/cirurgia , Idoso , Calcimiméticos/uso terapêutico , Cistos/fisiopatologia , Cistos/cirurgia , Humanos , Masculino , Neoplasias das Paratireoides/etiologia , Neoplasias das Paratireoides/cirurgia , Paratireoidectomia , Resultado do TratamentoRESUMO
Nintedanib, a triple tyrosine kinase inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor, has been used in idiopathic pulmonary fibrosis and adenocarcinoma in advanced non-small cell lung cancer. Although vascular endothelial growth factor inhibitors have been reported to cause endothelial injury and glomerular microangiopathy, nintedanib-induced glomerular microangiopathy has not been reported. A 68-year-old man with a history of primary aldosteronism, idiopathic pulmonary fibrosis, and pleomorphic carcinoma of the lung developed proteinuria and leg edema after nintedanib initiation. Kidney biopsy revealed prominent endothelial and mesangial injury. Proteinuria improved after nintedanib withdrawal. To the best of our knowledge, this is the second case report of nintedanib-induced glomerular microangiopathy. Although the incidence of nephropathy among patients receiving nintedanib is unknown at this moment, we recommend monitoring urinary protein excretion and blood pressure in patients receiving nintedanib and performing kidney biopsy to determine any histopathological change.
Assuntos
Fibrose Pulmonar Idiopática/tratamento farmacológico , Indóis/efeitos adversos , Nefropatias/induzido quimicamente , Inibidores de Proteínas Quinases/efeitos adversos , Proteinúria/induzido quimicamente , Idoso , Carcinoma/diagnóstico , Carcinoma/tratamento farmacológico , Endotélio Vascular/efeitos dos fármacos , Endotélio Vascular/lesões , Mesângio Glomerular/irrigação sanguínea , Mesângio Glomerular/efeitos dos fármacos , Mesângio Glomerular/lesões , Humanos , Hiperaldosteronismo/tratamento farmacológico , Indóis/administração & dosagem , Indóis/uso terapêutico , Rim/irrigação sanguínea , Rim/efeitos dos fármacos , Nefropatias/patologia , Neoplasias Pulmonares/patologia , Masculino , Inibidores de Proteínas Quinases/administração & dosagem , Inibidores de Proteínas Quinases/uso terapêutico , Receptores de Fatores de Crescimento de Fibroblastos/efeitos dos fármacos , Receptores do Fator de Crescimento Derivado de Plaquetas/efeitos dos fármacos , Receptores de Fatores de Crescimento do Endotélio Vascular/efeitos dos fármacos , Microangiopatias Trombóticas/induzido quimicamente , Microangiopatias Trombóticas/diagnóstico , Suspensão de TratamentoRESUMO
Hypomagnesemia, a side effect of proton-pump inhibitors (PPIs), can be asymptomatic. The presence of hypocalcemia or hypokalemia is indicative of hypomagnesemia; however, the concomitant use of PPIs and thiazide may mask hypocalcemia. A 79-year-old woman with a history of chronic heart failure and chronic kidney disease developed symptomatic hypocalcemia and hypomagnesemia. Five weeks earlier, she had developed thiazide-induced hyponatremia, so thiazide had been discontinued. Reviewing the patient's charts revealed that three discontinued thiazide administrations in the clinical course had unmasked hypocalcemia. Our case demonstrates that thiazide-induced hypercalcemia can be so prominent as to mask PPI-induced hypocalcemia and hypomagnesemia.
Assuntos
Hipercalcemia/induzido quimicamente , Hipocalcemia/induzido quimicamente , Deficiência de Magnésio/induzido quimicamente , Inibidores da Bomba de Prótons/efeitos adversos , Inibidores de Simportadores de Cloreto de Sódio/efeitos adversos , Idoso , Feminino , Insuficiência Cardíaca/tratamento farmacológico , Humanos , Hipopotassemia/induzido quimicamente , Hiponatremia/induzido quimicamente , Inibidores da Bomba de Prótons/uso terapêuticoRESUMO
The efficacy and safety of denosumab for the treatment of immobilization-related hypercalcemia in end-stage renal disease remain uncertain. We describe the case of a hemodialysis patient with immobilization-related hypercalcemia who was successfully treated with denosumab. A 79-year-old man admitted for hemodialysis after sustaining an acute kidney injury developed immobilization-related hypercalcemia due to the impairment resulting from an acute myocardial infarction, acute heart failure, and catheter-related bloodstream infection. After admission, the patient's corrected serum calcium rose to 12.9 from 8.8 mg/dL. A bisphosphonate (alendronate) was administered, but it was ineffective. Subsequently, treatment with denosumab proved to be effective and his corrected serum calcium level declined to 9.3 mg/dL within 1 week. Hypocalcemia, which is an adverse effect of denosumab, was prevented using active vitamin D and calcium supplementation, and his calcium level stabilized. Thus, our case demonstrates that denosumab is a viable therapeutic option for dialysis patients experiencing immobilization-related hypercalcemia.